About Biogen

 

 

We are pioneers in neuroscience. Pioneers dedicated to the discovery and development of innovative therapies for global patient populations with neurological and neurodegenerative diseases. Since our inception more than 40 years ago, we embarked on a ceaseless journey to discover solutions for patients that need them the most.

Our focus on neuroscience, our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society. While the fear of failure to tackle complex challenges in neurology keeps others away, at Biogen, we are not afraid to go where others won’t.


Founded in 1978, as one of the world’s first global biotechnology companies, Biogen today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy and commercializes biosimilars of advanced biologics. We are seeking U.S. regulatory approval for the potentially first early Alzheimer’s disease treatment, and continue to advance research in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology and pain.